Asahi Life Asset Management CO. LTD. Reduces Stock Holdings in 10x Genomics, Inc. (NASDAQ:TXG)

Asahi Life Asset Management CO. LTD. reduced its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 53.8% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,030 shares of the company’s stock after selling 1,200 shares during the quarter. Asahi Life Asset Management CO. LTD.’s holdings in 10x Genomics were worth $202,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Clarus Group Inc. acquired a new stake in 10x Genomics during the 1st quarter valued at approximately $14,459,000. BlackRock Inc. grew its stake in 10x Genomics by 2.8% during the 1st quarter. BlackRock Inc. now owns 5,307,139 shares of the company’s stock valued at $960,591,000 after purchasing an additional 144,119 shares in the last quarter. Baillie Gifford & Co. grew its position in shares of 10x Genomics by 260.4% in the 2nd quarter. Baillie Gifford & Co. now owns 5,030,996 shares of the company’s stock worth $985,169,000 after acquiring an additional 3,634,870 shares in the last quarter. ARK Investment Management LLC grew its position in shares of 10x Genomics by 22.7% in the 2nd quarter. ARK Investment Management LLC now owns 4,300,037 shares of the company’s stock worth $842,033,000 after acquiring an additional 795,916 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. grew its position in shares of 10x Genomics by 42.4% in the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,739,374 shares of the company’s stock worth $340,604,000 after acquiring an additional 518,185 shares in the last quarter. Institutional investors and hedge funds own 69.62% of the company’s stock.

In other news, CEO Serge Saxonov sold 15,000 shares of the stock in a transaction on Tuesday, September 7th. The stock was sold at an average price of $188.42, for a total value of $2,826,300.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Benjamin J. Hindson sold 41,666 shares of 10x Genomics stock in a transaction on Wednesday, September 1st. The shares were sold at an average price of $177.50, for a total value of $7,395,715.00. The disclosure for this sale can be found here. Insiders sold a total of 124,515 shares of company stock valued at $22,634,631 in the last quarter. 11.57% of the stock is currently owned by corporate insiders.

Shares of NASDAQ TXG opened at $155.67 on Wednesday. The firm has a 50-day moving average of $174.73 and a two-hundred day moving average of $176.80. 10x Genomics, Inc. has a twelve month low of $115.39 and a twelve month high of $208.99. The company has a market capitalization of $17.26 billion, a price-to-earnings ratio of -32.91 and a beta of 1.27.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings results on Tuesday, August 3rd. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.26) by $0.16. The company had revenue of $115.84 million for the quarter, compared to analysts’ expectations of $112.85 million. 10x Genomics had a negative return on equity of 8.38% and a negative net margin of 124.24%. The firm’s revenue was up 170.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.41) earnings per share. On average, sell-side analysts anticipate that 10x Genomics, Inc. will post -0.51 EPS for the current year.

Several research analysts have recently commented on TXG shares. Citigroup decreased their target price on 10x Genomics from $240.00 to $220.00 and set a “buy” rating for the company in a research report on Thursday, August 5th. Bank of America lowered 10x Genomics from a “buy” rating to a “neutral” rating and set a $180.00 target price for the company. in a research report on Tuesday. Finally, Zacks Investment Research lowered 10x Genomics from a “hold” rating to a “sell” rating in a research report on Saturday, August 7th. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $194.89.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.

Featured Story: What is the Federal Reserve?

Want to see what other hedge funds are holding TXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics, Inc. (NASDAQ:TXG).

Institutional Ownership by Quarter for 10x Genomics (NASDAQ:TXG)

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.